Skip to main content
. 2024 Mar 6;16(5):1071. doi: 10.3390/cancers16051071

Figure 4.

Figure 4

Impact of immune-molecular therapy (IMT) on survival with embedded adjusted hazard ratio (AHR) and 95% confidence interval (CI) in propensity-score-balanced patients diagnosed with stage IVB cervical cancer between 2013 and 2019 and treated with first-line therapy with chemotherapy (CT) alone (A), CT and external beam radiation (CT + EBRT) treatment (B), or CT + EBRT and intracavitary brachytherapy (ICBT) treatment (C).